A Potential Treatment Could Reduce the Severity of Sleep Apnea by 30%

A new study shows that the combination of two existing medications can reduce the severity of sleep apnea by at least 30%.

Sleep Apnea

Sleep Apnea. Image Courtesy of Drcamachoent

The study, published in The Journal of Physiology, involved 12 people with sleep apnea between the ages of 13 and 52. The patients participated in a double-blind, randomized, placebo-controlled crossover study. Led by Danny Eckert, professor, and director of the Adelaide Institute for Sleep Health at Flinders University in Australia, the study reused two existing medications to test their effectiveness in controlling the condition.

Read Also: Sleep Apnea: What Are CPAP Machines Used For?

Previous research showed that two drugs, reboxetine, and hyoscine butylbromide, were able to keep muscles active during sleep in patients without sleep apnea. The 2 drugs also improved their ability to breathe.

Improved breathing capacity

In adapting the drugs, the researchers sought to determine how and if reboxetine and butyl bromide could successfully address the root causes of sleep apnea. The scientists sought to balance the electrical activity of the muscles around the airways, prevent throat closure during sleep, and improve the regulation of carbon dioxide and breathing during sleep.

The results of their experiments showed that these drugs helped increase muscle activity around the participants’ airways and could reduce the severity of the patients’ sleep apnea by up to a third.

“Current treatment options for people with sleep apnea are limited and can be a painful journey for many,” Prof. Eckert points out. “We will then investigate the long-term effects of these and similar drugs. We will look at whether we can get the benefits of one drug without having to use both,” he adds.

Read Also: RMIT Study Shows That Obstructive Sleep Apnea Could Lead to Alzheimer’s

1  in 15 people is affected in the US

Sleep apnea is a disorder of the upper respiratory tract characterized by stops in breathing that can last more than 20 seconds. The airways extending from the back of the nose to the throat close repeatedly during sleep, limiting oxygen delivery and disturbing sleep.

According to Ineedbettersleep.com in the US 1 in 15 persons suffers from sleep apnea. The number of car accidents is seven times higher in people with sleep apnea. It is estimated that more than one in five people with type 2 diabetes has sleep apnea.

Patients with untreated sleep apnea are also more likely to suffer from cardiovascular disease and are also at higher risk of dementia and depression.

This would be welcomed news for the millions of sufferers if this study leads to the use of these 2 drugs for the treatment of sleep apnea.

Read Also: University of Michigan: Irregular Sleep Patterns Could Lead to Depression

References

The noradrenergic agent reboxetine plus antimuscarinic hyoscine butylbromide reduces sleep apnoea severity: A double-blind, placebo-controlled, randomized crossover trial

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373477

FEEDBACK:

Conversation

Want to Stay Informed?

Join the Gilmore Health News Newsletter!

Want to live your best life?

Get the Gilmore Health Weekly newsletter for health tips, wellness updates and more.

By clicking "Subscribe," I agree to the Gilmore Health and . I also agree to receive emails from Gilmore Health and I understand that I may opt out of Gilmore Health subscriptions at any time.